RareResearch.AI
← Back to atlas

R138G

Category 3/4 — Most DruggableUncertain significanceCytoplasmic · predictedSource card
ArginineGlycine at position 138 · N-terminal cytoplasmic (intrinsically disordered) · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference
Wild-type R138 — hydrogen bond to V142
Fullscreen ↗
DynaMut2 mutant · R138G
Mutant G138 — hydrogen bond to A141 lost (9 contacts lost)
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

9 lost0 gained5 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondP100Lost
Hydrogen bondA133A133Preserved
Hydrogen bondA141Lost
Hydrogen bondV142V142Preserved
Polar contactP100Lost
Polar contactT104Lost
Polar contactA133A133Preserved
Polar contactE140Lost
Polar contactA141Lost
Polar contactV142V142Preserved
Van der WaalsK101Lost
Van der WaalsA133A133Preserved
HydrophobicA133Lost
HydrophobicA141Lost

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-1.06kcal/mol
Destabilising — moderate
AlphaMissense
0.609
likely pathogenic
AlphaFold pLDDT
89
model confidence
Schema
Cat 3/4
Category 3/4 — Most Druggable
ΔΔG confidence: Standard confidence · Cytoplasmic

This variant is in a water-facing region, which is the regime the stability predictor was built and benchmarked for. Ordinary predictor error still applies.

Clinical Evidence

ClinVar classificationUncertain significance
Review statuscriteria provided, single submitter
Associated conditionsInborn genetic diseases
Population frequency (gnomAD v4)Ultra-rare · AF 0.000070%
cDNA changec.412C>G
ClinVar accessionVCV004201395
Last evaluated2025/08/31 00:00

Observed at very low frequency in gnomAD.

Classified for1★ unverified submission

ClinVar classifies this variant as Uncertain significance, but does not state what it is classified for. ClinVar records the condition only as "Inborn genetic diseases". A classification without a phenotype and an inheritance mode cannot be read as a statement about Wolfram syndrome risk or severity.

  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: 1★ single submitter. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
AF 0.000070% · 1 / 1,434,060 alleles
Homozygotes
0

Every ancestry group with observed alleles falls below the reporting threshold (min 2 alleles, min 500 sampled) — too sparse to name a highest-frequency population.

No homozygotes reported in gnomAD v4. For a recessive allele this is expected and is not, on its own, evidence either way.

Ancestry groupAllele freq.AC / ANHom.Carrier est.
Admixed American · under-sampled0.0025%1 / 40,3800

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Full Variant Card

WFS1 Wolframin — R138G Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Arginine → Glycine at position 138. N-terminal cytoplasmic (intrinsically disordered). ClinVar Uncertain significance, AlphaMissense 0.609, DynaMut2 ΔΔG -1.06 kcal/mol (destabilising).


Identity

FieldValue
VariantR138G (p.Arginine138Glycine)
DNA changec.412C>G
Gene · ProteinWFS1 · Wolframin (890 aa)
UniProtO76024 · WFS1_HUMAN
ClinVar accessionVCV004201395
Amino acid changeArginine (R) → Glycine (G)

Structural Context

FieldValue
AlphaFold modelAF-O76024-F1, v6
pLDDT at residue 13889.06 — well-folded
DomainN-terminal cytoplasmic (intrinsically disordered)
Position contextN-terminal cytoplasmic (intrinsically disordered)
IDR flagNo — pLDDT above 50 threshold

UniProt features at this position:

(none catalogued)

Position 138 sits in N-terminal cytoplasmic (intrinsically disordered). The wild-type residue is positively charged (arginine — guanidinium, strong H-bond donor); the mutant is small/flexible (glycine — backbone flexibility, no sidechain). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.


Computational Predictions

AlphaMissense

FieldValue
am_pathogenicity0.6085
am_classlikely pathogenic
InterpretationLikely pathogenic (threshold 0.564)

DynaMut2

FieldValue
ΔΔG (kcal/mol)-1.06 (Destabilising)
Job ID178092131018
Result URLJob 178092131018 · retrieved 2026-06-08 — result self-hosted by RareResearch.AI (Biosig no longer serves this page)

Clinical Evidence

Inheritance and scope

Uncertain significance — phenotype scope not stated in ClinVar

ClinVar classifies this variant as Uncertain significance, but does not state what it is classified for. ClinVar records the condition only as "Inborn genetic diseases". A classification without a phenotype and an inheritance mode cannot be read as a statement about Wolfram syndrome risk or severity.

Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient. Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

FieldValue
ClassificationUncertain significance
Review statuscriteria provided, single submitter
Last evaluated2025/08/31 00:00
InheritanceInheritance pattern not specified in ClinVar entry; WFS1 has both AD and AR presentations.
WFS1 variant landscapeR138G is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)
  • Inborn genetic diseases

Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 3/4 — Most Druggable

<strong>Category 3/4 — Most Druggable</strong><br/><br/>|ΔΔG|=1.06 < 2 kcal/mol (fold intact) + AlphaMissense 0.609 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Why this card matters. Wolframin's fold survives this substitution (|ΔΔG|=1.06 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.609. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.


Files in this folder

  • AF-O76024-F1-model_v6.pdb — AlphaFold structure
  • R138G_molstar_viewer.html — interactive 3D viewer (auto-highlights position 138 with ball-and-stick + neighbors within 5Å)
  • R138G_variant_card.md — this card (source of truth)
  • R138G_variant_card.html — styled printable card
  • R138G_dynamut2_summary.html — clean offline DynaMut2 result card
  • dynamut2_result.json — structured result data
  • dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
  • R138G_wildtype_interactions.pse / R138G_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the R138G PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download R138G PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.